Abstract 7P
Background
In early-stage of breast cancer, the analysis of lymph node metastasis(LNM) and molecular subtypes is conductive to clinical diagnosis and treatment decision-making. Here we proposed a new Deep learning network architecture, called DeepCALM, Conducted with Attention mechanism to united genomics and pathology, that can simultaneously predict LNM and Molecular subtypes.
Methods
In this retrospective study, DeepCALM was designed to analyse the breast cancer subtype and the degree of metastasis, which include the feature extraction from the digital pathological whold-slide images(WSIs), feature fusion between the feature of WSIs and RNA expression matrix, and muti-task classification. The WSIs and RNA expression data are all from The Cancer Genome Atlas(TCGA), and involved 916 breast cancer patients (2536 WSIs) that were split into training cohort of 734 patients (2021 WSIs) and validation cohort of 182 patients (515 WSIs), and the 219 survival-related gene that screened with the Random forest algorithm from training cohort. Model performances were evaluated using area under the curve (AUC), sensitivity, and specificity.
Results
DeepCALM achieved favourable accuracy for the classification of LNM(macro-average AUC of 0.977, sensitivity of 0.647, specificity of 0.953) and molecular subtypes(macro-average AUC of 0.960, sensitivity of 0.628, specificity of 0.941) in the training cohort, and LNM(AUC of 0.986, sensitivity of 0.647, specificity of 0.953) and molecular subtypes(AUC of 0.955, sensitivity of 0.628, specificity of 0.941) in the validation cohort (all p < 0.001).
Conclusions
The difference between LNM and molecular subtypes of breast cancer can be precisely distinguished by DeepCALM, which helps clinicians effectively determine the stage of tumor diffusion and speed up the diagnosis and accuracy, and then offer treatment or surgery plans.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
29P - Targeting CXCR4 promotes antitumor immunity through TOX-mediated CD8+ T cell activation
Presenter: Canhui Cao
Session: Poster viewing 01
30P - Investigation of KRAS G12C inhibitor JAB-21822 as a single agent and in combination with SHP2 inhibitor JAB-3312 in preclinical cancer models
Presenter: Peng Wang
Session: Poster viewing 01
31P - Photothermal responsive, nucleolin-targeted bimetallic nano-vehicle delivered the combinational therapeutics for improved pancreatic cancer treatment
Presenter: Kandasamy Saravanakumar
Session: Poster viewing 01
32P - Tumor growth inhibition effect of PLAG by regulation of neutrophil infiltration in ICI insensitivity B16F10 melanoma
Presenter: Guen Tae Kim
Session: Poster viewing 01
33P - Establishment of personalized therapeutic for salivary gland cancers based on patients-derived salivary tumoroid model
Presenter: Yoonjin Roh
Session: Poster viewing 01
34P - Association of ACRBP gene polymorphism (+26A/G) to liver cancer and diabetes leads to novel biomarker discovery
Presenter: Md Shariful Islam
Session: Poster viewing 01
35P - Exploring plerixafor as a vector molecule in nuclear medicine for targeting CXCR4 receptor overexpression in vivo
Presenter: Tamanna Lakhanpal
Session: Poster viewing 01
36P - Preclinical evaluation of novel MCL-1 degrader in in vitro and in vivo cancer models
Presenter: Piotr Kowalczyk
Session: Poster viewing 01
37P - Development of splice switching antisense oligonucleotides targeting midkine
Presenter: Graham Robertson
Session: Poster viewing 01
38P - Hormonal modulation of photodynamic therapy efficacy in breast cancer 3D spheroid culture model
Presenter: MN Leung
Session: Poster viewing 01